DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Introduction
Transition-metal-based compounds constitute a class of chemotherapeutics, which are widely used in the clinic as antitumor and antiviral agents. The interest in this structural class has its origin in the 1960s, with the serendipitous discovery by Rosenberg of the inhibition of division of bacterial cells by platinum complexes (Rosenberg et al., 1965, Rosenberg et al., 1969). The first transition-metal anticancer drug introduced in the clinic was cisplatin [cis-diamminedichloroplatinum(II)]. This very simple inorganic molecule, which belongs to bifunctional reagents, is highly effective for the treatment of testicular and ovarian cancer and is used in combination regimens for a variety of other carcinomas, including bladder, small cell lung and head and neck cancers (Weiss and Christian, 1993, Wong and Giandomenico, 1999, Giaccone, 2000, Ho et al., 2003). However, its clinical utility is limited to a relatively narrow range of tumors, because of primary resistance to cisplatin and the development of resistance secondary to the initial treatment (Wernyj and Morin, 2004). In addition, cisplatin is administered intravenously due to its limited solubility in water and has severe side effects (Wong and Giandomenico, 1999).
These limitations have prompted a search for more effective and less toxic alternative metal-based antitumor agents. The result has been the synthesis of thousands of platinum complexes and their evaluation as antitumor agents. Of these, only few have reached clinical trials and have been approved for clinical administration. They are close analogues of cisplatin, namely carboplatin [cis-diamminecyclo-butanedicarboxylato-platinum(II)], oxaliplatin {[(1R,2R-diamminocyclohexane)oxalato-platinum(II)] (1,2-diaminocyclo-hexane = DACH)} and nedaplatin [cis-diammineglycolato-platinum(II)]. Thus, the search for new metal-based antitumor drugs has continued beyond platinum, in the hope of improvements in cancer treatment.
There have been efforts to rationally design unconventional platinum complexes, such as polynuclear platinum compounds (Farrell, 2004) and analogues of clinically ineffective trans-diamminedichloroplatinum(II) (transplatin) (Farrell, 1996, Perez et al., 2000, Brabec, 2002, Natile and Coluccia, 2004, Brabec and Kasparkova, 2005a). Additional efforts have been directed in the design of other transition-metal antitumor agents (Clarke et al., 1999, Brabec, 2002, Alessio et al., 2004a). Theoretical advantages in using ions of transition metals other than platinum include:
- a.
the availability of additional coordination sites in octahedral complexes and altered shape of the complex,
- b.
alterations in ligand affinity and substitution kinetics,
- c.
changes in oxidation state,
- d.
photodynamic approaches to therapy.
Section snippets
Ruthenium complexes
Ruthenium complexes have attracted much attention as building blocks for new transition-metal-based antitumor agents. Ruthenium compounds offer the potential over antitumor platinum(II) complexes currently used in the clinic of reduced toxicity, a novel mechanism of action, the prospect of non-cross-resistance (Zeller et al., 1991, Coluccia et al., 1993) and a different spectrum of activity (Clarke, 2003, Alessio et al., 2004a). Non-cross-resistance in cisplatin-resistant cancer cells and
Conclusions and future directions
Several ruthenium compounds are transported into cells relatively easily and bind to cellular DNA. While the initial DNA binding site of several ruthenium complexes is the same as that of conventional cisplatin and its analogues, their DNA binding mode is different. The major adduct formed on DNA by cisplatin is the intrastrand cross-link formed between two neighboring purine residues. This cross-link, which is a likely candidate for the lesion responsible for antitumor effects of cisplatin,
Acknowledgements
This work was supported by grants from the Grant Agency of the CR (305/05/2030 and 203/06/1239), the Academy of Sciences of the CR (1QS500040581), and Ministry of Education of the CR (MSMT LC06030). It is a pleasure to thank all our collaborators, especially Bernhard Keppler, Enzo Alessio, and Peter J. Sadler for their expertise and for providing us with the new ruthenium complexes discussed in this review. The authors also acknowledge that this work was also carried out within the
References (86)
- et al.
Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[{trans-RuCl4(Me2SO)}2(μ-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation
J. Inorg. Biochem.
(2000) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair
Prog. Nucleic Acid Res. Mol. Biol.
(2002)- et al.
Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs
Drug Resist. Update
(2005) Ruthenium metallopharmaceuticals
Coord. Chem. Rev.
(2003)- et al.
Cisplatin: from DNA damage to cancer chemotherapy
Prog. Nucleic Acid Res. Mol. Biol.
(2001) - et al.
Antileukemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukemia and on P388/DDP subline
Eur. J. Cancer
(1993) - et al.
Cellular effects of transferrin coordinated to Cl(NH3)5RuCl2 and cis-Cl2(NH3)4RuCl
J. Inorg. Biochem.
(2001) - et al.
DNA as a possible target for antitumor ruthenium(III) complexes—a spectroscopic and molecular biology study of the interactions of two representative antineoplastic ruthenium(III) complexes with DNA
Arch. Biochem. Biophys.
(2000) - et al.
Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl2]
J. Inorg. Biochem.
(2003) - et al.
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells
Cancer Lett.
(2005)
Mechanisms of resistance to cisplatin
Mutat. Res.
Recognition of cisplatin adducts by cellular proteins
Mutat. Res.
The binding properties of two antitumor ruthenium(III) complexes to apotransferrin
J. Biol. Chem.
Mixed-metal polymetallic platinum complexes designed to interact with DNA
Inorg. Chim. Acta
Modification of natural, double-helical DNA by antitumor cis- and trans-[Cl2(Me2SO)4Ru] in cell-free media
Biochem. Pharmacol.
Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA-binding proteins and repair. Relationship to cytotoxicity
Chem. Biol.
Current status of the development of trans-platinum antitumor drugs
Crit. Rev. Oncol. Hematol.
Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel
Drug Resist. Update
Chemoresistance in rat ovarian tumours
Eur. J. Cancer
New metal complexes as potential therapeutics
Curr. Opin. Chem. Biol.
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer
Br. J. Cancer
Ruthenium anticancer drugs
Ruthenium antimetastatic agents
Curr. Top. Med. Chem.
Ruthenium in medicine: current clinical uses and future prospects
Platinum Met. Rev.
Interaction of cis- and trans-RuCl2(DMSO)4 with the nucleotides GpA, d(GpA), ApG, d(ApG) and d(CCTGGTCC): high-field NMR characterization of the reaction products
J. Biol. Inorg. Chem.
Metals and DNA: molecular left-handed complements
Science
Chiral discrimination in the covalent binding of bis(phenanthroline)dichlororuthenium(II) to B-DNA
J. Am. Chem. Soc.
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines
J. Pharmacol. Exp. Ther.
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells
Anti-cancer Drugs
Efficacy of new ruthenium complexes against chemically-induced autochthonous colorectal-carcinoma in rats
Anticancer Res.
DNA interactions of platinum anticancer drugs. Recent advances and mechanisms of action
Light-induced anticancer activity of [RuCl2(DMSO)4] complexes
J. Med. Chem.
Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts
J. Am. Chem. Soc.
Covalent interaction of Ru(terpy)(tmephen)Cl+ with DNA: a potential ruthenium-based anticancer drug
J. Chin. Chem. Soc.
Non-platinum chemotherapeutic metallopharmaceuticals
Chem. Rev.
Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry
Polynuclear platinum drugs
Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine-L1210 and human tumor panels and studies on their mechanism of action
Cancer Res.
J. Met.-based Drugs
New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumour cells
Cancer Res.
Recent developments in the field of tumor-inhibiting metal complexes
Curr. Pharm. Des.
Antitumor activity of some ruthenium derivatives in human colon cancer cell lines in vitro
Arzneimittel—Forschung/Drug Research
Anticancer activity of cisplatin and related complexes
Cited by (356)
Residual levels and health risk assessment of trace metals in Chinese resident diet
2024, Journal of Environmental Sciences (China)Exploring benzene Ru(II) complexes of 2-subsitituted quinoline/napthyridine ligands: Synthesis, biomacromolecular binding and DFT investigations
2024, Journal of Molecular StructureTransition metals in angiogenesis – A narrative review
2023, Materials Today Bio